TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Suicide Plus Immune Gene Therapy for Advanced Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically and / or cytologically confirmed melanoma.~* Patients progressed or are intolerant to conventional systemic treatments.~* Patients that are not candidates for surgery under oncologic criteria (complete resection).~* Performance status (ECOG) 0 or 1.~* Patients with life expectancy greater than 6 months.~* Patients with at least one accessible target lesion for gene inoculation (superficial localizations of the primary tumor, satelitosis, subcutaneous or accessible lymph node metastasis).~* Patients with measurable disease (according to RECIST 1.1 criteria, irrespective of the target lesion chosen for suicide gene inoculation)~* Patients with signed informed consent.~Exclusion Criteria:~* Patients with uncontrolled cardiovascular disease~* Patients with uncontrolled respiratory disease.~* Patients with uncontrolled immune disease.~* Patients with glucocorticoids or immunosuppressive drugs or agents with immunomodulatory activity (except non-steroidal anti-inflammatory agents) up to 2 weeks before treatment.~* Patients performing other experimental therapies.~* Patients who are pregnant or breastfeeding.~* Patients undergoing concurrent chemotherapy or radiation therapy.~* Uncontrolled diabetes.~* Patients with active diagnosis of other malignant neoplasms.~* HIV-positive patients.~* Uncontrolled thyroid abnormality.~* Patients with significant medical morbidity.~* Patients with a history of allergic reactions to chemicals or similar to those used in this study.~* Metastasis in the central nervous system.~* Laboratory eligibility criteria excluded:~  * Hemoglobin: \<8 g / dL, leukocytes: \<3,000 / mm3, platelets: \<100,000 / mm3, neutrophils: \<1000 / mm3, hematocrit: \<25%. bilirubin\> 2.0 mg / dL, GOT or GPT: 2.5 times\> than normal upper institutional limit (ULN), alkaline phosphatase: 2 times\> ULN, creatinine\> 2.0 mg / dL, creatinine clearence : \<60 ml / min / 1.73 m2.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Suicide plus immunogene therapy (Type: EXPERIMENTAL): Intra and peritumoral infiltrates with multiple injections of lipoplexes carrying the HSVtk suicide gene co-administered with GCV and subcutaneous vaccine produced with formolized allogeneic tumor extracts and lipoplexes carrying hIL-2 and hGM-CSF genes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Admitted to the intensive care unit~* Positive COVID-19 PCR~* Mechanical Ventilation for ≤ 48 hours~* PaO2/FiO2 ≤300~Exclusion Criteria:~* Heparin allergy~* Active bleeding~* Death or withdraw of care anticipated by intensivist within 24 hours~* Platelets\< 50,000 cells/µL~* Clinically significant coagulopathy, as decided by the intensivist~* O2 dependent at baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nebulized Heparin (Type: EXPERIMENTAL): Heparin 5,000 units/mL Dose: 25,000 units Frequency: every 6 hours Duration: 10 days
- Placebo (Type: PLACEBO_COMPARATOR): 0.9% Sodium Chloride Dose: 5 mL Frequency: every 6 hours Duration: 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient was on low-dose aspirin treatment on the day when consent was obtained, and requires the long-term continuous treatment even after treatment with the investigational drug is started.~* The patient was confirmed to have a history of gastric ulcer or duodenal ulcer.~Exclusion Criteria:~* Endoscopically confirmed gastric and/or duodenal ulcers on Day 1.~* Endoscopically confirmed active upper gastrointestinal hemorrhage on Day 1.~* Current or past history of aspirin-induced asthma or hypersensitivity to nonsteroidal anti-inflammatory drugs.~* Past or planned surgery affecting gastric acid secretion.~* Clinically significant hepatic or renal disorder.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lansoprazole 15 mg QD (Type: EXPERIMENTAL): None
- Gefarnate 50 mg BID (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults \>18 yrs of age~* WHO defined MDS with Higher risk MDS (IPSS int-2/high)~* Azacitidine X at least 6 cycles with no hematologic improvement/no disease progression as per IWG 2006 criteria~* Ferritin \>500 µg/L~* If transfusion independent, must have Hb \<110 g/L OR Neutrophils \< 1,000/mL OR Platelets \< 100,000/mL~* ECOG ≤2~* CrCl \>40 ml/min~Exclusion Criteria:~* Increased ALT (\>300 U/L)~* Uncontrolled infection~* HIV+~* Pregnant or breast-feeding~* Previous and concurrent iron chelation~* Concurrent use of hematopoietic growth factors including erythropoietin, darbepoietin and granulocyte colony stimulating factor~* Concurrent use of other disease modifying agents including cytotoxic chemotherapy, histone deacetylase inhibitors, other hypomethylating agents or lenalidomide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deferasirox + Azacitidine (Type: EXPERIMENTAL): Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles + Deferasirox 10-30 mg/kg/d depending on transfusion needs
- Azacitidine (Type: ACTIVE_COMPARATOR): Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Delayed Umbilical Cord Clamping Versus Cord Milking in Preterm Neonate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Singleton or multiples pregnancies in patients admitted for medically indicated delivery or in advanced spontaneous preterm labor with imminent delivery at 24 0/7 - 28 6/7 weeks gestation~* Women ages 18 and older~Exclusion Criteria:~* Planned vaginal breech delivery~* Major fetal abnormalities (defined as those that are lethal or require prenatal or postnatal surgery)~* Fetal death in utero~* Red cell isoimmunization~* Patients who are incapable of informed consent (unconscious, severely ill, mentally handicapped), or are unwilling to undergo randomization~* Placenta previa or other known abnormal placentation (e.g. placenta accreta)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Delayed cord clamping (Type: EXPERIMENTAL): Delayed cord clamping for 30 seconds
- Milking of the cord (Type: EXPERIMENTAL): Milking of the cord 4 times in 10 seconds
- Immediate cord clamping (Type: NO_INTERVENTION): Immediate cord clamping after delivery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is at least 18-years of age.~2. Clinical and imaging diagnosis of a symptomatic Isolated cavernous malformation or Familial cavernous malformation~3. MRI Imaging Grade Type I or Type II (see Table 1)~4. Patient is considered a candidate for surgical resection of their cavernous malformation~5. Written and informed consent obtained prior to the study enrollment.~6. Negative pregnancy test at time of enrollment for women of child-bearing potential.~7. Heart rate greater than 50 beats per minute~8. Systolic blood pressure \> 90 mmHg~Exclusion Criteria:~1. Subject is less than 18-years of age.~2. History of allergy to propranolol or other beta blockers.~3. Patient is already taking another beta blocker for cardiac indications.~4. History of asthma presently requiring any active treatment (oral medications or inhalers).~5. History of cardiac dysfunction (as defined by the New York Heart Association Functional Classification grade II, III or IV).~6. Heart rate \< 50 beats per minute~7. Systolic blood pressure \< 90 mmHg~8. History of diabetes and currently on any anti-hyperglycemic medication.~9. Pregnant and lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treatment group (Type: EXPERIMENTAL): A Treatment group of ten (n=10) patients that will receive oral propranolol at a dose of 60mg per day (one 60mg ER capsule per day) for 7- to 10-days prior to surgery plus their usual medications.
- Control Group (Type: OTHER): A control group of 10 (n=10) patients will receive only their routine medications (no propranolol) during the (-7 to -10 days) preoperative period. A control group (n=10) is required to allow for a semi-quantitative comparison with mRNA and miRNA levels in the treatment group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Glucose Monitoring Initiation at Hospital Discharge

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older~2. Have diabetes (type 1 diabetes mellitus, type 2 diabetes mellitus, cystic fibrosis related diabetes mellitus)~3. Hemoglobin A1c greater than or equal to 8.0% or history of hypoglycemia unawareness~4. Able and willing to sign informed consent form~5. Have a valid telephone number~6. Willing to purchase FreeStyle Libre 2 CGM sensors out of pocket after discharge from hospital (when insurance coverage isn't available)~Exclusion Criteria:~1. Unable to sign informed consent form~2. Have altered mental status~3. Unable to manage diabetes independently at home~4. Have utilized CGM in the past~5. Pregnancy~6. New steroid-induced hyperglycemia~7. Unwilling to participate in the study~8. Have kidney disease requiring hemodialysis~9. Taking high doses of vitamin C daily (greater than 500 mg every day)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CGM Intervention (Type: EXPERIMENTAL): All eligible patients will receive a Continuous Glucose Monitor (CGM) prior to hospital discharge after signing an informed consent.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Dose and Response of Intrathecal Hydromorphone in Patients Undergoing Cesarean Section at Virginia Commonwealth University Health System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists physical status classification less than or equal to 3 Elective cesarean section Able to obtain a signed consent in English Patients who are 18 years or older~Exclusion Criteria:~* ASA greater than 3 or major medical comorbidities that are not optimized Patient refusal or contraindications to neuraxial/study drugs. Allergy to study drugs Conversion to general anesthesia Any patient who does not receive any multimodal regimen (PO acetaminophen, +/- PO ibuprofen/IV ketorolac) Any patient who is taking PO/IV opioids or buprenorphine during the current pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Intrathecal Dilaudid (Type: EXPERIMENTAL): This will be a prospective up/down dosage study. After obtaining informed consent, eligible participants will be part of an up/down dose titration study. This first phase of our study will be conducted using intrathecal (spinal) hydromorphone to determine an appropriate dose range for our study population. Study drug dose will initially be 40 mcg. The only deviation from the current standard of care will be that patients will be given hydromorphone intrathecally instead of morphine. The rest of the care provided will be standard of care and per current practices at VCU labor and delivery floor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Keratoconus on Stress at Work

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients with keratoconus all stages followed at the CHU Gabriel Montpied,~* patients constituting a representative control group of workers consulting in ophthalmology service of Clermont-Ferrand.~Exclusion Criteria:~* an other ophtalmological disease alters visual acuity.~* minors subjects~* inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- KERATOCONUS group (Type: None): All workers with keratoconus all stages followed at the service of ophthalmology in CHU Gabriel Montpied, Clermont-Ferrand, Auvergne.~The investigators only assessed data from usual routine practice. Patients answer the auto questionnaire in last minutes of consultation.
- CONTROL group (Type: None): workers with good visual acuity consulting in ophthalmology service of Clermont-Ferrand.~The investigators only assessed data from usual routine practice. Patients answer the auto questionnaire in last minutes of consultation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Myfortic - Treatment for Extensive cGvHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 - 60~* Any primary diagnosis requiring treatment by hematopoietic stem cell transplantation~* Recipient of a single allogeneic stem cell transplant (bone marrow or peripheral blood stem cells, or cord blood) minimum 80 days ago~* Received a graft from a related or an unrelated donor~* Conditioning regimen: Myeloablative or non-myeloablative~* Patients suffering a first episode of extensive chronic GvHD, without recurrent disease~* The diagnosis of chronic GvHD requires the following:~  * Distinction from acute GvHD~ * Presence of at least one diagnostic clinical sign of chronic GvHD or presence of at least one distinctive sign confirmed by pertinent biopsy or other relevant diagnostic tests~ * Exclusion of other possible diagnoses~* Receiving a standard prophylaxis regimen for acute GvHD: CsA plus methotrexate, or CSA+MMF for NMA, or a T-cell depleted transplant~* Patient gives written informed consent prior to randomization~Exclusion Criteria:~* Patient age less than 18 years or over 60 years.~* GvHD prophylaxis by tacrolimus plus methotrexate~* Delayed onset acute GvHD following NMA or DLI~* Second allogeneic stem cell transplant~* Not the first episode of chronic GvHD needing systemic immunosuppressive therapy.~* Limited chronic GvHD (Seattle criteria, see Appendix 1)~* Uncontrolled systemic infection which in the opinion of the investigator is associated with an increased risk of the patient's death within 1 week of randomization~* In the opinion of the investigator, if the patient has significant medical or psychosocial problems or unstable disease status~* Pregnant or lactating females~* Known hypersensitivity to mycophenolic acid

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Myfortic (Type: ACTIVE_COMPARATOR): Patients in this arm will receive Myfortic + Prednisone + Cyclosporine
- Standard Care/ Placebo (Type: OTHER): In this arm patients will receive Prednisone + Cyclosporine + Placebo or Prednisone + Cyclosporine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Signed informed consent form in accordance with institutional guidelines~* Histologically or cytologically confirmed primary CNS lymphoma documented by brain biopsy or cerebrospinal fluid or vitrectomy analysis~* CD20 positive disease~* Progressive or relapsed disease during or after completion of prior methotrexate-based chemotherapy~* Aged 18 months to 75 years~* Performance status ECOG 0-3 OR Karnofsky 30-100%~* Hematocrit at least 25% (transfusion or epoetin alfa allowed)~* Absolute granulocyte count at least 1,200/mm\^3~* Platelet count at least 100,000/mm\^3 OR at least lower limit of normal~* Bilirubin no greater than 2.0 times upper limit of normal~* Creatinine less than 1.8 mg/dL~* Calculated Creatinine clearance (CrCl) at least 50 mL/min~* Adequate cardiac function to tolerate general anesthesia~* Adequate pulmonary function to tolerate general anesthesia~* Available for follow-up for 1 year post therapy~* Fertile patients must use effective contraception for a minimum of 2 months before and during study participation~EXCLUSION CRITERIA:~* Radiographic signs of intra-cranial herniation and/or spinal block~* HIV positive~* Systemic lymphoma~* Positive serum HCG, pregnant or lactating~* Allergy to study agents~* Hepatitis B or hepatitis C positive

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- All subjects (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Esophageal Metaplasia Using a Novel Antibody: Reversibility by Proton Pump Inhibitor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Dyspeptic symptoms, upper abdominal pain, heartburn, regurgitation;~* Endoscopically - normal appearing GE junction, irregular z-line, or erosive esophagitis up to Grade 2.~Exclusion Criteria:~* Barrett's esophagus (Endoscopically greater than 2 cm of columnar epithelium on endoscopy and the presence of specialized columnar epithelium on histology);~* Patients who have been taking a PPI longer than the 3 months proceeding study entry. Patients currently taking a PPI but for less than 3 months who are not willing to discontinue PPI treatment for 4 weeks prior to enrollment into this study.~* Severe esophagitis Grade 3 or 4~* Documented active duodenal or gastric ulcer (at least 0.5cm diameter). Patients with erosions can be included.~* Presence of esophageal varices~* History of gastric surgery altering normal anatomy (eg, Billroth procedure, gastric bypass)~* Pregnant or nursing patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues